• Memory Pharma Rockets on Clinical Trial Enrollment

    Shares of drug maker Memory Pharmaceuticals Corp. (NASDAQ: MEMY), skyrocketed on Monday, after the company announced it had has completed enrollment for Phase IIa trials of its Alzheimer’s treatment on Thursday. The market was closed on Friday.